Skip to content
imbria logo (1)
  • Company
    • Mission & Values
    • Our Team
    • Board of Directors
    • Investors
    • Contact
  • Science & Pipeline
    • Pipeline
    • Ninerafaxstat
    • Publications & Presentations
  • Patients & Families
    • nHCM
    • HFpEF
    • Clinical Trials
      • Expanded Access Policy
  • Investors & Media
    • Press Releases
imbria logo (1)
  • Company
    • Mission & Values
    • Our Team
    • Board of Directors
    • Investors
    • Contact
  • Science & Pipeline
    • Pipeline
    • Ninerafaxstat
    • Publications & Presentations
  • Patients & Families
    • nHCM
    • HFpEF
    • Clinical Trials
      • Expanded Access Policy
  • Investors & Media
    • Press Releases

Press Releases

Imbria Pharmaceuticals to Present Phase 2a Data from the Ninerafaxstat Program at the European Society of Cardiology Congress 2022

August 22, 2022
Read More »

Imbria Appoints John Young to its Board of Directors

March 24, 2022
Read More »

Imbria Pharmaceuticals to Participate at SVB Leerink Biopharma Private Company Connect

March 22, 2022
Read More »

Imbria Pharmaceuticals Strengthens Executive Leadership Team with New Appointments

March 10, 2022
Read More »

Imbria Pharmaceuticals Announces initiation of enrollment in IMPROVE-HCM, a Phase 2 Study Investigating the safety, tolerability, and efficacy of IMB-1018972 (IMB-101) in patients with non-obstructive hypertrophic cardiomyopathy

July 19, 2021
Read More »

Imbria Pharmaceuticals announces enrolment of the first 10 patients in IMPROVE-DiCE, an exploratory Phase 2 study investigating the impact of IMB-1018972 on cardiac energetics, metabolism and function in patients with type 2 diabetes

June 22, 2021
Read More »
Page1 Page2 Page3 Page4 Page5
  • Company
  • Science & Pipeline
  • Patients & Families
  • Investors & Media
  • Company
  • Science & Pipeline
  • Patients & Families
  • Investors & Media
CONTACT

Privacy Policy      Terms of Use

2025 © Imbria Pharmaceuticals​

Linkedin